NASDAQ · DOMH
Dominari Holdings Inc.
$1.72-$0.03 (-1.71%)
Dominari Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.88% below the high.
Loading market information…
NASDAQ · MEIP · USD
Stock price, dividends, earnings
Quote as of Sep 10, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
MEI Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow MEI Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refractory follicular lymphoma and a Phase Ib multi-arm study targeting B-cell malignancies. Additionally, Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, is undergoing Phase Ib clinical trials for acute myeloid leukemia and other B-cell malignancies. The company is also advancing ME-344, a mitochondrial inhibitor that targets the oxidative phosphorylation complex, through Phase I development for HER2-negative breast cancer. Completing its portfolio is Pracinostat, an orally administered histone deacetylase inhibitor, which is being evaluated in a Phase II clinical trial for myelodysplastic syndrome. MEI Pharma has forged strategic collaborations, including comprehensive license, development, and commercialization agreements with Kyowa Kirin Company and Helsinn Healthcare SA (the latter also encompassing manufacturing). It further holds a clinical collaboration with BeiGene, Ltd. and a licensing agreement with Presage Biosciences, Inc. Founded in 2000 as Marshall Edwards, Inc., the company rebranded to MEI Pharma, Inc. in July 2012 and maintains its corporate headquarters in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
18 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.72-$0.03 (-1.71%)
Dominari Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.88% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
$3.10-$0.17 (-5.2%)
PHAXIAM Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.15% below the high.
$13.60-$2.51 (-15.58%)
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
$1.21+$0.02 (+1.68%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.85% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
CA$8.75-CA$0.25 (-2.78%)
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.9% below the high.
